ATI RN
ATI Pharmacology Proctored
1. A drug ending in the suffix (pril) is considered a ______.
- A. H
- B. ACE inhibitor
- C. Antifungal
- D. Beta agonist
Correct answer: B
Rationale: Drugs with names ending in -pril are classified as angiotensin-converting enzyme (ACE) inhibitors. These medications are commonly used to manage conditions like high blood pressure, heart failure, and diabetic kidney disease by blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased blood pressure.
2. A client has a new prescription for Warfarin. The nurse should identify that the concurrent use of which of the following medications increases the client's risk of bleeding?
- A. Vitamin K
- B. Calcium carbonate
- C. Acetaminophen
- D. Ranitidine
Correct answer: C
Rationale: The correct answer is Acetaminophen. Acetaminophen, especially in high doses, can increase the risk of bleeding in clients taking warfarin. Warfarin works by inhibiting the clotting factors dependent on vitamin K, so Vitamin K intake should be consistent but not excessive. Calcium carbonate and ranitidine do not significantly increase the risk of bleeding when used concurrently with Warfarin.
3. A client with Preeclampsia is receiving Magnesium Sulfate IV continuous infusion. Which of the following findings should the nurse report to the provider?
- A. 2+ deep tendon reflexes
- B. 2+ pedal edema
- C. 24 mL/hr urinary output
- D. Respirations 12/min
Correct answer: C
Rationale: In a client receiving Magnesium Sulfate IV for Preeclampsia, a urinary output less than 25 to 30 mL/hr indicates magnesium sulfate toxicity and should be reported to the provider for further evaluation and management. Choice A, 2+ deep tendon reflexes, is a normal finding with magnesium sulfate therapy. Choice B, 2+ pedal edema, is expected in clients with preeclampsia but does not indicate magnesium sulfate toxicity. Choice D, respirations 12/min, is within the normal range and not a concerning finding related to magnesium sulfate administration.
4. When caring for a client prescribed warfarin, which laboratory test should the nurse monitor to evaluate the therapeutic effect of the medication?
- A. aPTT
- B. Platelet count
- C. BUN
- D. PT/INR
Correct answer: D
Rationale: The correct laboratory test to monitor the therapeutic effect of warfarin is the PT/INR. Warfarin affects blood clotting, and the PT/INR levels indicate the effectiveness of the medication in preventing clot formation. Therefore, monitoring PT/INR levels helps ensure that the client is within the therapeutic range and is protected from potential complications related to clotting. Choice A (aPTT) is incorrect because while it measures the clotting time, it is not the preferred test for monitoring warfarin therapy. Choice B (Platelet count) is incorrect as it assesses the number of platelets and not the medication's therapeutic effect. Choice C (BUN) is unrelated to monitoring the effects of warfarin therapy and is primarily used to assess kidney function.
5. Which statement is true about food and drug precautions?
- A. Limiting certain types of food or administering certain types of drugs is necessary.
- B. Certain combinations of food and drugs can cause adverse reactions.
- C. Precautions may involve limiting certain types of food or administering drugs rather than restricting the drug itself.
- D. When one drug alters the way another drug affects the body.
Correct answer: B
Rationale: The correct answer is B. Certain combinations of food and drugs can indeed lead to adverse reactions. It is important to be cautious with the simultaneous intake of food and drugs as interactions between them can affect their efficacy and safety. Choices A, C, and D are incorrect because they do not accurately reflect the potential risks associated with the combination of food and drugs.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access